Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation

Annals of Transplantation

Volumn 17, Issue 4, 2012, Pages 52-58

  Keller, Frieder ^a   Wiesner, Susanne ^a   Bunjes, Donald ^a   Hartmann, Bertram ^a   Schmitt, Michael ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Efficacy; Everolimus; Hematopoietic stem cell transplant; Kidney transplant; Side effects

Indexed keywords

CREATININE; EVEROLIMUS;

ADULT; ARTICLE; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84875333534     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883694     Document Type: Article

References (35)

1. Pascual J: Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant, 2006; 21: 18-23
2. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M et al, Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 2009; 87: 233-42
3. Procopio G, Verzoni E, Iacovelli R et al: Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther, 2011; 11: 1631-40
4. Coppin C, Kollmannsberger C, Le L et al: Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int, 2011; 108: 1556-63
5. Baselga J, Campone M, Piccart M et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012; 366: 520-29
6. Platzbecker U, von Bonin M, Goekkurt E et al: Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant, 2009; 15: 101-8
7. Morath C, Arns W, Schwenger V et al: Sirolimus in renal transplantation. Nephrol Dial Transplant, 2007; 22: 61-65
8. Tenderich G, Fuchs U, Zittermann A et al: Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant, 2007; 21: 536-43
9. Gridelli C, Maione P, Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist, 2008; 13: 139-47
10. Rostaing L, Kamar N: mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol, 2010; 23: 133-42
11. Dantal J, Berthoux F, Moal MC et al: Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int, 2010; 23: 1084-93
12. Albano L, Alamartine E, Toupance O et al: Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant, 2012; 17: 58-67
13. De Simone P, Metselaar HJ, Fischer L et al: Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transplant, 2009; 15: 1262-69
14. Vallin M, Guillaud O, Morard I et al: Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant, 2011; 25: 660-69
15. Pascual J, Marcén N, Ortuń J: Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation, 2005; 79: 80-84
16. Tobinai K, Ogura M, Maruyama D et al: Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol, 2010; 92: 563-70
17. Luft T, Dietrich S, Falk C et al: Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood, 2011; 118: 1685-92
18. Pham PT, Danovitch GM, Wilkinson AH et al: Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation, 2002; 74: 1077-80
19. Pratap B, Abraham G, Srinivas CN, Bhaskar S: Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Saudi J Kidney Dis Transpl, 2007; 18: 609-12
20. Yýlmaz VT, Koçak H, Avcý AB et al: Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol, 2011; 43: 581-84
21. Bilbao I, Sapisochin G, Dopazo C et al: Indications and management of everolimus after liver transplantation. Transplant Proc, 2009; 41: 2172-76
22. Moro JA, Almenar L, Martínez-Dolz L et al: Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc, 2008; 40: 3034-36
23. Marcén R: Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs, 2009; 69: 2227-43
24. Stracke S, Helmchen U, von Müller L et al: Polyoma virus-associated interstitial nephritis in a patient with acute myeloic leukaemia and peripheral blood stem cell transplantation. Nephrol Dial Transplant, 2003; 18: 2431-33.
25. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med, 2004; 351: 2715-29
26. Rehm B, Keller F, Mayer J, Stracke S: Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc, 2006; 38: 711-13
27. Calle L, Tejada C, Lancho C, Mazuecos A: Pneumonitis caused by sirolimus: improvement after switching to everolimus. Nefrologia, 2009; 29: 490-91
28. White DA, Schwartz LH, Dimitrijevic S et al: Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol, 2009; 4: 1357-63
29. White DA, Camus P, Endo M et al: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med, 2010; 182: 396-403
30. Rothenburger M, Teerling E, Bruch C et al: Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' followup. J Heart Lung Transplant, 2007; 26: 250-57
31. Rodríguez-Moreno A, Ridao N, Garcá-Ledesma P et al: Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc, 2009; 41: 2163-65
32. Doi T, Muro K, Buko N et al: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol, 2010; 28: 1904-10
33. Johnston PB, Inwards DJ, Colgan JP et al: A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol, 2010; 85: 320-24
34. Yee KW, Zeng Z, Konopleva M et al: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res, 2006; 12: 5165-73
35. Dabydeen DA, Jagannathan JP, Ramaiya N et al: Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer, 2012; 48(10): 1519-24